U.S. Markets closed

The Patient View: Biogen Alzheimer's Trial Participant Jeff Borghoff at Healthy Returns

When Biogen and its partner Eisai announced they were halting their clinical trial for Alzheimer's, Jeff Borghoff, a patient in the failed drug trial, was devastated. But he isn't giving up. Determined to find a treatment, he is exploring other possibilities. Here he shares important insights on the patient experience, alongside CNBC senior personal finance correspondent Sharon Epperson.